Biomay Launches Cas9 mRNA Off-the-Shelf in the Quality Grades GMP and RUO
(June 16th, 2025) Biomay is proud to announce the launch of mRNA-encoded spCas9 as a new catalog product. Immeditely available in both, GMP and RUO quality, Biomay’s Cas9 mRNA provides a streamlined path forward from discovery to clinical research. Biomay’s Cas9 mRNA portfolio includes multiple optimized formats—featuring distinct 5′ cap analogs, 3′ poly(A) tail lengths and various nucleoside modifications …
> More infoBiomay Launches FDA-Grade CRISPR/Cas9 Nuclease for Off-the-Shelf Purchase
(May 9th, 2025) Biomay announced the commercial availability of its CRISPR/Cas9 nuclease, marking a significant addition to its off-the-shelf product portfolio for genome-editing applications.
Clients purchasing Biomay’s Cas9 will benefit from the company’s unparalleled track record and expertise as a market-registered GMP-manufacturer of the nuclease …
Biomay Obtains FDA Approval for Manufacturing of Cas9 Nuclease
(April 28th, 2025) Biomay announced its successful approval by the U.S. Food and Drug Administration (FDA) for the manufacturing, testing and release of recombinant Cas9 nuclease from its headquarters site. Cas9 is an essential component of CRISPR-based gene editing therapies, including CASGEVY® (exagamglogene autotemcel) developed and launched by Vertex Pharmaceuticals …
> More infoBiomay Announces its Successful Support of Approval of First CRISPR/Cas9-based Therapy
(January 25th, 2024) Biomay, a biotech contract development and manufacturing organization based in Vienna, Austria,
announces successful completion of an FDA inspection qualifying Biomay as a cGMP manufacturer
and supplier of recombinant nuclease Cas9 for use in gene editing therapies.